Denosumab Biosimilars: Accelerating Drug Development for RANKL Inhibitors
Denosumab represents one of the leading biologics applied today in various diseases of bones: treatment and prevention of osteoporosis, bone metastases, and other skeletal disorders. Its success in improving patient health has made it one of the most impactful therapies in its field. With the growth of the biosimilar market in recent years and (...) Read more